RNAC · XBRL financial data

Cartesian Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RNAC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	26,004	38,913	2,797
Revenue from contracts with customers	16,597	85,077	110,777	26,004	38,275	400
Research and development	54,505	68,736	72,377	71,839	45,105	58,034
General and administrative	18,913	20,938	23,862	40,581	30,126	31,468
Total operating expenses	73,418	89,674	96,239	112,420	82,810	146,202
Operating income (loss)	(56,821)	(4,597)	14,538	(86,416)	(43,897)	(143,405)
Interest income	—	—	—	4,964	7,386	6,579
Interest expense	1,556	2,844	3,031	2,833	0	—
Other income (expense)	89	15	330	691	606	(2,010)
Income tax expense (benefit)	0	15,966	(609)	(19,000)	287	(9,193)
Net income (loss)	(68,876)	(25,687)	35,379	(219,710)	(77,424)	(130,302)
Earnings per share, basic‡ USD per share	(20.42)	(6.61)	7.21	(49.85)	(4.48)	(5.02)
Earnings per share, diluted‡ USD per share	(20.42)	(6.61)	3.00	(49.85)	(4.49)	(5.02)
Weighted average shares, basic‡ thousands of shares	3,370	3,807	4,820	5,165	17,277	25,973
Weighted average shares, diluted‡ thousands of shares	3,370	3,807	4,858	5,165	17,358	25,973

‡ Per-share figures and share counts are adjusted for the 1-for-30.030030030030026 stock split (April 2024); filings made before it reported them unadjusted.

Fiscal years (RNAC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	138,685	114,057	106,438	76,911	212,610	125,139
Marketable securities	0	13,998	28,164	0	—	—
Accounts receivable	7,224	9,914	6,596	5,870	872	1,115
Prepaid and other current assets	5,434	6,474	3,778	4,967	3,144	3,022
Total current assets	151,343	144,443	148,138	90,729	216,626	129,276
Property and equipment, net	1,395	2,142	2,794	2,113	9,912	12,185
Right-of-use asset	10,948	9,829	11,617	10,068	5,535	5,601
Goodwill	—	—	0	48,163	48,163	48,163
Total assets	165,435	159,883	165,886	305,050	435,023	296,411
Accounts payable	443	224	316	3,150	288	1,288
Accrued liabilities	8,146	10,533	14,084	14,733	12,076	9,498
Total current liabilities	81,547	72,251	25,077	68,209	22,976	14,937
Long-term debt	—	—	—	—	—	0
Lease liability, non-current	9,647	8,598	10,055	8,789	11,133	8,525
Total liabilities	183,441	137,362	72,058	444,680	441,825	422,651
Accumulated deficit	(404,629)	(430,316)	(394,937)	(614,647)	(692,071)	(822,373)
Total stockholders' equity	(18,006)	22,521	93,828	(440,184)	(6,802)	(126,240)
Total liabilities and equity	165,435	159,883	165,886	305,050	435,023	296,411
Common shares outstanding (cover page)‡ thousands of shares	3,742	4,139	5,106	5,393	25,907	26,509

‡ Per-share figures and share counts are adjusted for the 1-for-30.030030030030026 stock split (April 2024); filings made before it reported them unadjusted.

Fiscal years (RNAC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(68,876)	(25,687)	35,379	(219,710)	(77,424)	(130,302)
Stock-based compensation	5,422	7,720	11,194	22,524	6,582	10,521
Net cash from operating activities	34,881	(60,382)	(31,631)	(51,161)	(23,674)	(73,941)
Purchases of property and equipment	815	1,085	1,201	206	9,093	5,454
Net cash from investing activities	(741)	(17,140)	(15,002)	34,609	(8,742)	(5,454)
Proceeds from issuing common stock	2,108	51,958	2,121	—	—	—
Proceeds from long-term debt	24,736	0	0	—	—	—
Repayments of long-term debt	19,313	0	0	27,457	0	—
Net cash from financing activities	14,431	52,897	39,215	(13,145)	168,428	(8,055)
Net change in cash	48,513	(24,628)	(7,398)	(29,750)	135,991	(87,405)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33,419	14,359	(9,972)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026
TuHURA Biosciences	996	not reported	(8,634)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Fennec Pharmaceuticals	41,249	17,874	50*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Protara Therapeutics	17,076	not reported	(15,389)*	59.1M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Caribou Biosciences	26,194	1,499	(22,787)*	107.2M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Fate Therapeutics	32,429	2,082	(23,400)	119.8M	6.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.